JP Morgan analyst Jessica Fye maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and

Jazz Pharmaceuticals' financial results are improving. The company's oncology business could push sa

Estimated Q3 Financial Impacts Related to the Actio Biosciences, Inc. Acquisition In connection with

Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings b

Ziihera (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line

HJazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced updated overall survival (OS) results from t

Nearly 40% of patients alive at three years with Ziihera plus tislelizumab and chemotherapy, irrespe

Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweigh

CWA Asset Management Group LLC lifted its position in shares of Jazz Pharmaceuticals PLC (NASDAQ: JA

DUBLIN, Oct. 19, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it wil

Jazz Pharmaceuticals offers a differentiated medical cannabis play, with Epidiolex sales growth and

Jazz Pharmaceuticals is transforming beyond oxybate reliance, with diversified growth across sleep m

Cramer warns against Apple Hospitality if rates hit 6%, prefers Vylor over Corteva, backs Jazz, and

RBC Capital analyst Leonid Timashev maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperfor

Truist Securities analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy a

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi

Jazz Pharmaceuticals (NASDAQ: JAZZ - Get Free Report) and vTv Therapeutics (NASDAQ: VTVT - Get Free

Goldman Sachs analyst Andrea Newkirk reinstates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and

Iambic Therapeutics, an AI drug discovery company backed by Nvidia and the Qatar Investment Authorit

Jazz Pharmaceuticals (NASDAQ: JAZZ) outlined development and commercial plans for its oncology, epil

Jazz Pharmaceuticals (NASDAQ: JAZZ) executives outlined the company's oncology growth strategy, earl

Jazz Pharmaceuticals NASDAQ: JAZZ executives outlined the company's oncology growth strategy, early

Jazz Pharmaceuticals NASDAQ: JAZZ outlined development and commercial plans for its oncology, epilep

Jazz paid $820 million up front to acquire Actio Biosciences. Actio shareholders could receive anoth

Engineers Gate Manager LP cut its holdings in Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 93.2% durin

Jazz Pharmaceuticals plc (JAZZ) Presents at Deutsche Bank 2026 Healthcare Summit Transcript

Jazz Pharmaceuticals plc (JAZZ) Presents at Morgan Stanley 24th Annual Global Healthcare Conference

Acquisition adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1-re

UBS analyst Ashwani Verma maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the

Jazz Pharmaceuticals plc (JAZZ) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcr

Barclays analyst Etzer Darout maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced second interim top-line overall survival (OS)

Deutsche Bank analyst David Hoang maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and rai

Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweigh

FDA approves JAZZ's Ziihera-containing combination regimens for HER2-positive gastroesophageal

Truist Securities analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy a

Top analysts changed outlook on top names: Piper raised $INTU price target, Ascendiant raised $QUBT

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ("Jazz Pharmaceuticals") today announced that Jazz In

Needham analyst Ami Fadia maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the

AbCellera Biologics stock gains as investors react to Jazz Pharmaceuticals’ FDA approval and the com

FDA approves Jazz Pharmaceuticals' Ziihera combinations for first-line treatment of HER2-positiv

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the U.S. Food and Drug Administration (F

Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweigh

Actio Biosciences' lead clinical asset is ABS-1230, a novel, first-in-class small molecule preci

JP Morgan analyst Jessica Fye maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and

Truist Securities analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy a

TD Cowen analyst Joseph Thome maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises

Wells Fargo analyst Mohit Bansal maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight a

Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweigh

Piper Sandler analyst David Amsellem maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweig